| Symbol | XRTX |
|---|---|
| Name | XORTX THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3710-33RD STREET NW, CALGARY, Alberta, T2L 2M1, Canada |
| Telephone | 403-455-7727 |
| Fax | — |
| — | |
| Website | https://www.xortx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001729214 |
| Description | XORTX Therapeutics Inc is a clinical-stage biotechnology company. The company focused on developing drug therapies for orphan diseases like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes. Additional info from NASDAQ: |
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
Read moreXORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
Read moreXORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
Read moreXORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
Read more